# Cannabis use predicts worse clinical outcomes in newly psychotic patients > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-use-predicts-worse-clinical-outcomes-in-newly-psychotic-patients/ > **Published:** 2026-08-01T12:28:02-04:00 | **Last Modified / Clinically Audited:** 2026-09-08T20:17:34-04:00 > **Clinical Summary:** Cannabis use in first-episode psychosis predicts worse clinical outcomes at 24 months. Clinical insights for patient assessment and recovery optimization. --- ✦ New CED Clinical Relevance #50 [Clinical Context](https://cedclinic.com/cannabis-hyperemesis-syndrome-treatment-insights-2026/) Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. Mental HealthResearchTHCSafetyNeurologyAnxietyDosing Why This Matters Clinicians treating patients with first-episode psychosis should assess [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) as a modifiable risk factor, since this study indicates it is associated with poorer treatment outcomes over two years. Patients and families need counseling about cannabis’s potential to worsen psychotic symptoms and delay recovery, particularly during the critical early phase of psychotic illness when intervention has the greatest impact. This finding supports incorporating substance use screening and intervention into standard psychosis treatment protocols to improve long-term functional outcomes. Clinical Summary This prospective cohort study followed newly psychotic patients at baseline and at 6, 12, and 24 months to evaluate whether [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) predicted clinical outcomes during the critical early phase of psychotic illness. The findings demonstrated that [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) at baseline or during follow-up was associated with worse clinical trajectories, including greater symptom severity, poorer response to antipsychotic treatment, and higher rates of relapse across the two-year observation period. These results are consistent with existing evidence suggesting that cannabis may exacerbate psychotic symptoms and interfere with treatment response, particularly in individuals with emerging or first-episode psychosis who are neurobiologically vulnerable. For clinicians managing newly psychotic patients, this evidence underscores the importance of systematically screening for cannabis use and providing clear counseling about the risks of cannabis in this population, as continued use may significantly compromise treatment outcomes. The practical implication is that cannabis cessation should be considered a key therapeutic target and integrated into early intervention programs for psychosis to optimize symptom remission and long-term prognosis. Dr. Caplan’s Take “This prospective follow-up data is clinically meaningful because it tracks actual outcomes over two years rather than relying on cross-sectional snapshots, but we need to be careful about directionality here: we’re seeing an association between cannabis use and worse psychotic outcomes, yet we cannot definitively say cannabis caused the deterioration versus individuals with more severe underlying illness being more likely to use cannabis for symptom relief. That said, for patients already experiencing first-episode psychosis, the clinical signal is clear enough that we should counsel caution about cannabis use and monitor closely if they choose to continue.” Clinical Perspective 🧠 This longitudinal study adds to growing evidence that cannabis use is associated with poorer treatment response and clinical trajectories in first-episode psychosis, a finding with direct implications for initial psychiatric assessment and [patient counseling](https://cedclinic.com/stroke-risk-assessment-substance-use/). However, several methodological considerations warrant caution in interpretation: the direction of causality remains unclear, as cannabis use may be partly driven by untreated psychotic symptoms or attempts at self-medication rather than purely worsening outcomes, and unmeasured confounders such as substance use patterns, treatment adherence, social support, and genetic vulnerability could partially explain the association. The specific cannabis products, potency levels, and frequency of use were not detailed in this summary, limiting understanding of whether the risk is dose-dependent or driven by high-THC products. Clinically, these findings support the importance of systematically screening for cannabis use at first psychosis presentation, providing clear [patient education](https://cedclinic.com/medical-cannabis-patient-education-basics/) about the potential risks to illness course, and considering 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/mental-health/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Cannabis%20use%20predicts%20worse%20clinical%20outcomes%20in%20newly%20psychotic%20patients%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D71937)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D71937)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Cannabis%20use%20predicts%20worse%20clinical%20outcomes%20in%20newly%20psychotic%20patients%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D71937)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [Cannabis, Inflammation, and Anxiety: What the Research Shows](https://cedclinic.com/cannabis-inflammation-anxiety-sleep/) 📰 Source: [https://www.psypost.org/hopelessness-and-depression-slow-recovery-in-cannabis-induced-psychosis/](https://www.psypost.org/hopelessness-and-depression-slow-recovery-in-cannabis-induced-psychosis/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).